Date: 2017-05-02
Type of information: Nomination
Compound: corporate advisor
Company: Acceleron Pharma (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases - Neurological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On May 2, 2017, Acceleron Pharma announced that Steven Ertel , due to medical reasons, will transition from his role as executive vice president and chief operating officer to become a special advisor to the chief executive officer, effective immediately. Mr. Ertel was recently diagnosed with amyotrophic lateral sclerosis.
Steve joined Acceleron in January 2006 . During that time, he has led business development, commercial strategy, program management, corporate communications, manufacturing and quality functions. Steve has spent over 25 years in the biotechnology industry at Acceleron, Biogen Idec , Genentech , Synta , and Vivus.
Financial terms:
Latest news:
Is general: Yes
